EDS-EDS-26-001: Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Office of National Drug Control Policy notices from 2026.
Office of National Drug Control Policy offered grants of up to $500,000 (at least $1) to nonprofits and colleges and universities. It expected to make one award. Applications closed on August 31, 2026.
From the official notice on Grants.gov, last changed August 12, 2026. Checked November 7, 2026.
- Award ceiling$500,000
- Award floor$1
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | August 12, 2026 |
|---|---|
| Deadline | August 31, 2026 |
| Archived by Grants.gov | September 30, 2026 |
Who can apply
This opportunity was open to nonprofits and colleges and universities.
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Is this a realistic fit?
- Past Research and Data Analysis awards averaged $915,665; this notice allows up to $500,000 per award.
- Most of the program's money (65% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
This research project will help build local and national drug consumption surveillance, identify gaps in existing drug testing protocols, facilitate information exchange across public health and public safety organizations, and help coordinate an informed response to address the drug crisis.
Who has won Research and Data Analysis grants before
From fiscal 2021 to 2025, Research and Data Analysis (95.007) awarded $9.2 million across 10 grant awards, an average of $915,665 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Baltimore | Maryland | 2 | $5.9 million |
| National Association of County and City Health Officials | District of Columbia | 1 | $1.2 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 1 | $700,000 |
| University of Maryland, College Park | Maryland | 3 | $574,998 |
| American College of Medical Toxicology, Inc. | Arizona | 1 | $400,000 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is EDS-EDS-26-001 still open?
No. It closed on August 31, 2026.
Who can apply for Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition?
Office of National Drug Control Policy accepted applications from nonprofits and colleges and universities.
What is the deadline for Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition?
Closed August 31, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has won Research and Data Analysis grants before?
The largest recipients over five fiscal years were University of Baltimore, National Association of County and City Health Officials, National Foundation for the Centers for Disease Control & Prevention, Inc. The program made 10 awards worth $9.2 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)